Skip to main content
Premium Trial:

Request an Annual Quote

IP Roundup: Dec 22, 2009


Biocortech of Paris has received US Patent No. 7,635,558, "Method for analyzing nucleic acid and use thereof for evaluating the degree of mRNA editing of the serotonin 5-HT2C receptor." The patent claims a method for analyzing nucleic acids using a small-size probe array composed of deoxyinostines, rather than deoxyguanogines. The patent also claims probe arrays and their use in methods for detecting and quantifying target oilgonucleotides present in DNA or RNA molecules in a sample, in particular the mRNA editing rate of the serotonin 5-HT2C receptor.

Samsung Electronics has received US Patent No. 7,635,559, "Polynucleotide associated with a type II diabetes mellitus comprising single nucleotide polymorphism, microarray and diagnostic kit comprising the same, and method for analyzing polynucleotide using the same." The patent claims a method for determining increased risk of developing type II diabetes mellitus. The method includes determining the nucleotide at a specific polymorphic site in a nucleic acid sample, and determining if the person has an increased risk of developing type II diabetes mellitus. More specifically, the patent describes a process of hybridizing the nucleic acid sample onto a microarray on which is immobilized a polynucleotide containing at least 10 contiguous nucleotides of the specific sequence and detecting the hybridization result.

The Massachusetts Institute of Technology has received US Patent No. 7,635,563, "High throughput methods relating to microRNA expression analysis."The patent claims a method for identifying microRNA expression in a sample. The method includes: a) providing RNA composing a microRNA from a sample; b) appending at least two linkers to the microRNA; c) detectably labeling the microRNA; d) contacting a microarray with the detectably labeled microRNA; and e) detecting the binding of the detectably labeled microRNA to the microarray.

Agilent Technologies of Santa Clara, Calif., has received US Patent No. 7,635,564, "Biopolymeric arrays having replicate elements." The patent claims a method for fabricating an array by: a) grouping probes into ranked groups of probes, where probes that detect lower-abundance targets in a sample are grouped into a higher-ranked group and probes that detect higher-abundance targets in a sample are grouped into a lower-ranked group; b) designing an array composed of the ranked groups of probes; and c) fabricating the array.

Population Genetics Technologies of Cambridge, UK, has received US Patent No. 7,635,566, "Methods and compositions for isolating nucleic acid sequence variants." The patent describes a way of isolating sequence variants of a genetic locus of interest using a modified iterative primer extension method. The nucleic acids analyzed are generally single stranded and have a reference sequence that is used as a basis for performing iterative single nucleotide extension reactions from a hybridized polymerization primer, according to the patent. The iterative polymerization reactions are configured so that polymerization of the strand will continue if the sequence of the nucleic acid being analyzed matches the reference sequence. Polymerization will be terminated if the nucleic acid being analyzed does not match the reference sequence, the patent states. Nucleic acid strands that have mutations can be isolated using a variety of methods and sequenced to determine the precise identity of the mutation or polymorphism. By performing the method on both strands of the nucleic acid being analyzed, virtually all possible mutations can be identified, the patent claims.

Life Technologies has received US Patent No. 7,635,572, "Methods for conducting assays for enzyme activity on protein microarrays." The patent claims methods of conducting assays for enzymatic activity on microarrays that are useful for the large-scale study of protein function, screening assays, and high-throughput analysis of enzymatic reactions. Specifically, the patent describes a way of conducting enzymatic assays using a microarray, where a protein and a substance are immobilized on the surface of a solid support and where the protein and the substance are in proximity to each other sufficient for the occurrence of an enzymatic reaction between the substance and the protein.

Abbott Laboratories of Des Plaines, Ill., has received US Patent No. 7,636,636, "Imaging microarrays." The patent claims a method of obtaining a corrected image of a microarray. The method includes acquiring an image of a microarray including a target spot, and processing the image to correct for background noise and chip misalignment. The method also includes analyzing the image to identify a target patch, edit debris, and correct for ratio bias; and detecting single copy number variation in the target spot using an objective statistical analysis that includes a t-value statistical analysis.

Roche NimbleGen has received US Patent No. 7,636,637, "Variable length probe selection." The patent claims a method for high-throughput mutation mapping and genome resequencing by using a variable length probe selection algorithm to rationally select probes used in designing oligonucleotide arrays synthesized by maskless array synthesis technology. Also described is a variable length probe selection algorithm used in designing such oligonucleotide arrays.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.